Patent ID: 7662794

Claim:
A method of treating a cardiovascular disease in a subject involving neointima formation in the subject which comprises administering to the subject an amount of a catalytic deoxyribonucleic acid effective to inhibit neointima formation in the subject so as to thereby treat the cardiovascular disease in the subject, wherein the catalytic deoxyribonucleic acid specifically cleaves an mRNA having the sequence set forth in SEQ ID NO:5 encoding a Plasminogen Activator Inhibitor-1 (PAI-1) and comprises, in 5′ to 3′ order: (a) consecutive nucleotides defining a first binding domain of at least 4 nucleotides; (b) consecutive nucleotides defining a catalytic domain located contiguous with the 3′ end of the first binding domain, and capable of cleaving the PAI-1-encoding mRNA at a predetermined phosphodiester bond; and (c) consecutive nucleotides defining a second binding domain of at least 4 nucleotides located contiguous with the 3′ end of the catalytic domain, wherein the sequence of the nucleotides in each of the first and second binding domains is complementary to a sequence of ribonucleotides in the PAI-1-encoding mRNA and wherein the catalytic deoxyribonucleic acid hybridizes to and specifically cleaves the PAI-1-encoding mRNA, wherein the catalytic deoxyribonucleic acid comprises SEQ ID NO:2, 3 or 4, and wherein the administration is intracarotid administration, or is by intracardiac injection, or is local administration.